Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study

Abstract

Objective

Preterm delivery for preeclampsia or placental insufficiency (PREPI) is a clinical criterion for antiphospholipid syndrome (APS), but no prior prospective studies have used the international classification criteria for APS. Our objective is to determine the proportion of women with PREPI who test positive for aPL using international criteria for antiphospholipid antibody (aPL) assays.

Methods

We conducted a prospective, case-control study of 148 women delivered < 36 weeks because of PREPI compared to 148 controls. PREPI cases delivered < 36 weeks were compared to matched controls. Cases and controls were tested for aPL. Demographic variables were compared with chi-squared and Wilcoxon-rank-sum statistics. Rates of + aPL were compared using adjusted odds ratios (aORs) for maternal body mass index (BMI) and Caucasian race. Positive aPL (+aPL) was defined as lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin G (IgG) (GPL) or immunoglobulin M (IgM) (MPL) ≥ 40, or anti-β2-glycoprotein I (aβ2GPI) IgG (SGU) or IgM (SMU) ≥ 40.

Results

Controls were more likely to be Caucasian (87% vs 70%, p = 0.006) and had lower BMIs (BMI 26 vs 33, p < 0.001). Positive aPL were found more commonly in cases than controls (11.5% vs 1.4%, aOR 8.9 (95% CI 1.9–41.4)). In + aPL cases, 76% had + LA, 41% had + aCL, and 24% had + aβ2GPI.

Conclusion

Women requiring early delivery for PREPI are more likely to have aPL (and thus APS) than controls. This is the first prospective study using both obstetric definitions and laboratory criteria in accordance with APS international criteria.

Keywords

Anticardiolipin antibodies antiphospholipid syndrome pregnancy

Get full access to this article

View all access options for this article.

References

Miyakis

Lockshin

Atsumi

et al.

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Yamada

Atsumi

Kobashi

et al.

Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009; 79: 188–195.

Yamada

Atsumi

Amengual

et al.

Anti-beta2 glycoprotein-I antibody increases the risk of pregnancy-induced hypertension: A case-controlled study. J Reprod Immunol 2010; 84: 95–99.

Chauleur

Galanaud

Alonso

et al.

Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost 2010; 8: 699–706.

Polzin

Kopelman

Robinson

Read

Brady

. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol 1991; 78: 1108–1111.

do Prado

Piovesan

Staub

Horta

. Association of anticardiolipin antibodies with preeclampsia: A systematic review and meta-analysis. Obstet Gynecol 2010; 116: 1433–1443.

Abou-Nassar

Carrier

Ramsay

Rodger

. The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis. Thromb Res 2011; 128: 77–85.

Branch

Andres

Digre

Rote

Scott

. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989; 73: 541–545.

Yasuda

Takakuwa

Tokunaga

Tanaka

. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995; 86: 555–559.

10.

Lee

Brown

Branch

Ward

Silver

. Anticardiolipin and anti-β2-glycoprotein-I antibodies in preeclampsia. Obstet Gynecol 2003; 102: 294–300.

11.

Dreyfus

Hedelin

Kutnahorsky

et al.

Antiphospholipid antibodies and preeclampsia: A case-control study. Obstet Gynecol 2001; 97: 29–34.

12.

Allen

Tapia-Santiago

Kutteh

. Antiphospholipid antibodies in patients with preeclampsia. Am J Reprod Immunol 1996; 36: 81–85.

13.

Facchinetti

Marozio

Frusca

et al.

Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 2009; 200: 46. e1–e5.

14.

Mello

Parretti

Marozio

et al.

Thrombophilia is significantly associated with severe preeclampsia: Results of a large-scale, case-controlled study. Hypertension 2005; 46: 1270–1274.

15.

Faden

Tincani

Tanzi

et al.

Anti-beta 2 glycoprotein I antibodies in a general obstetric population: Preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta 2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Obstet Gynecol 1997; 73: 37–42.

16.

Bowen

Moodley

Dutton

Fickl

. Antibodies to oxidised low-density lipoproteins and cardiolipin in pre-eclampsia and eclampsia. J Obstet Gynaecol 2002; 22: 123–126.

17.

Harris

Spinnato

. Should anticardiolipin tests be performed in otherwise healthy pregnant women?. Am J Obstet Gynecol 1991; 165(5 Pt 1): 1272–1277.

18.

Kupferminc

Fait

Many

Gordon

Eldor

Lessing

. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 2000; 96: 45–49.

19.

Pattison

Chamley

McKay

Liggins

Butler

. Antiphospholipid antibodies in pregnancy: Prevalence and clinical associations. Br J Obstet Gynaecol 1993; 100: 909–913.

20.

Alfirevic

Mousa

Martlew

Briscoe

Perez-Casal

Toh

. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet Gynecol 2001; 97(5 Pt 1): 753–759.

21.

Kaleli

Aktan

Turan

Akşit

. Antiphospholipid antibodies in eclamptic women. Gynecol Obstet Invest 1998; 45: 81–84.

22.

Mello

Parretti

Martini

et al.

Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies. Haemostasis 1999; 29: 197–203.

23.

Milliez

Lelong

Bayani

et al.

The prevalence of autoantibodies during third-trimester pregnancy complicated by hypertension or idiopathic fetal growth retardation. Am J Obstet Gynecol 1991; 165: 51–56.

24.

Moodley

Bhoola

Duursma

Pudifin

Byrne

Kenoyer

. The association of antiphospholipid antibodies with severe early-onset pre-eclampsia. S Afr Med J 1995; 85: 105–107.

25.

Rix

Stentoft

Aunsholt

Dueholm

Tilma

Høier-Madsen

. Lupus anticoagulant and anticardiolipin antibodies in an obstetric population. Acta Obstet Gynecol Scand 1992; 71: 605–609.

26.

Wharfe

Fletcher

Reid

. Lupus anticoagulant in Jamaican primiparae and the clinical significance in asymptomatic patients. West Indian Med J 1999; 48: 126–128.

27.

Katano

Aoki

Sasa

Ogasawara

Matsuura

Yagami

. beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996; 11: 509–512.

28.

Lynch

Rutledge

Stephens

et al.

Longitudinal measurement of anticardiolipin antibodies during normal pregnancy: A prospective study. Lupus 1995; 4: 365–369.

29.

Stuart

Kornman

McHugh

. A prospective study of pregnancy outcome in women screened at a routine antenatal clinic for anticardiolipin antibodies. Br J Obstet Gynaecol 1993; 100: 599–600.

30.

Uncu

Ozan

Küçükerdoğan

Cengiz

. Anticardiolipin antibodies in pregnancy induced hypertension. Obstet Gynecol 1996; 70: 97–100.

31.

Valdés-Macho

Cabiedes

Villa

Cabral

Alarcón-Segovia

. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy. Arch Med Res 2002; 33: 460–465.

32.

van Pampus

Dekker

Wolf

et al.

High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1146–1150.

33.

De Carolis

Caruso

Ferrazzani

Carducci

De Santis

Mancuso

. Poor pregnancy outcome and anticardiolipin antibodies. Fetal Diagn Ther 1994; 9: 296–299.

34.

de Jesus

Agmon-Levin

Andrade

et al.

14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014; 13: 795–813.

35.

American College of Obstetricians and Gynecologists. Methods for estimating the due date. Committee Opinion No. 700. Obstet Gynecol 2017; 129: e150–e154.

36.

Roberts

August

Bakris

et al.

Hypertension in pregnancy: Executive summary. Obstet Gynecol 2013; 122: 1122–1131.

37.

Pengo

Tripodi

Reber

et al.

Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–1740.

38.

Oken

Kleinman

Rich-Edwards

Gillman

. A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr 2003; 3: 6.

39.

Harris

Taylor

Thielke

Payne

Gonzalez

Conde

. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.

40.

Cohen

Buurma

Goemaere

et al.

Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol 2011; 225: 502–511.

41.

Girardi

Berman

Redecha

et al.

Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644–1654.

42.

Holers

Girardi

et al.

Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211–220.

43.

Pierangeli

Girardi

Vega-Ostertag

Liu

Espinola

Salmon

. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 2120–2124.

44.

Salmon

Girardi

Holers

. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 2003; 12: 535–538.

45.

Girardi

Mackman

. Tissue factor in antiphospholipid antibody-induced pregnancy loss: A pro-inflammatory molecule. Lupus 2008; 17: 931–936.

46.

Shamonki

Salmon

Hyjek

Baergen

. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196: 167. e1–e5.